e13a3或e14a3转录本约占CML人群的0.36%,该转录本缺乏编码SH3结构域的ABL第二外显子[42],导致阿思尼布耐药[43]。. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.